PR Newswire All News ReleasesCodex · 实盘不做把握 5/10不做原因:无增量信息
北京时间·🕒 发布 04:37:00·⟳ 抓取 04:38:28 +1m28s·⚡ 决策 08-28 14:02:00 +9h23m·60.2 天前
Pomerantz就Hims & Hers既有FTC诉讼和Visa投诉事件发起投资者索赔调查
本条不是FTC/Visa事件本身的首发，而是基于既有负面新闻的律师调查广告；缺少新增可量化损害与可执行价格，不能开新空，也不构成做多反转。
📄 原文PR Newswire All News Releases↗ 原文
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Hims & Hers Hea…
不做 Hims & Hers Health（HIMS.US）
Pomerantz调查公告只是基于已公开FTC诉讼和Visa投诉报道的律师招揽，新增事实和量级不足；缺少实时行情与干净先例支撑，不开新空。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Hims & Hers面临的FTC诉讼和Visa投诉监控均已在7月29日和8月21日分别公开并触发股价下跌；8月27日Pomerantz公告只是证券索赔调查招揽，没有披露新的监管进展、赔偿金额、业务中断或财务下修。事件方向偏负面但增量弱，当前更适合回避新交易而非追空。
消息传播链
- FTC披露已起诉Hims，指控其分享敏感健康信息并存在误导计费和取消订阅问题，这是Pomerantz公告引用的主要基础事实。市场反应:Pomerantz公告称Hims当日收跌14.73%至25.00美元。
- Bloomberg报道称Hims因减重订阅业务信用卡争议过高被Visa纳入Acquirer Monitoring Program，9月费用约7.5万美元。市场反应:Pomerantz公告称Hims在8月24日收跌7.99%至31.08美元。
- Pomerantz发布投资者索赔调查公告，但未披露新的监管文件、损失金额或公司回应。
关键理由
- FTC官方已在2026-07-29披露对Hims的隐私、计费和取消流程诉讼，Pomerantz公告引用的是这条旧事实。
- Bloomberg/Visa投诉监控报道已在2026-08-21公开，公告提到的约7.5万美元费用相对公司规模不是新的重大量级。
- 律师事务所调查公告通常是索赔招揽，只有升级为正式诉讼、和解金额或披露责任证据时才可能形成更强负面催化。
主要风险
- 若后续出现正式集体诉讼、FTC禁令或高额罚款，Hims的合规成本和订阅业务留存预期可能继续下修。
- 本轮缺少真实行情和事件研究工具结果，不能给出可回测的入场价、止损和先例胜率。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-27 · 影响 weakens
未在Pomerantz公告中看到新增正式诉讼、赔偿金额、监管升级或业绩下修；做空催化强度不足。
检索:Hims Hers Pomerantz investigation new lawsuit damages August 27 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足使本次不升级为可执行SHORT；最终以新增事实不足和price-in风险高为主导。
方向:律师事务所调查公告方向偏负面，但其可交易性通常弱于监管首发、正式诉讼或财务下修。
涨幅量级:未取得可量化外部event_study结果，不能用历史样本校准涨跌幅。
形态:本条属于旧负面后的索赔广告，见光后继续单独重定价的证据不足。
原文全文
展开原文 · 2,499 字
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Hims and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 29, 2026, the Federal Trade Commission ("FTC") filed a lawsuit against Hims, accusing it of sharing customers' medical information with third-party advertisers. The FTC's criminal complaint accuses Hims of "deceptive and unlawful privacy practices," including sharing sensitive details about patient health with Meta Platforms, Snap and Facebook's parent company.
On this news, Hims' stock price fell $4.32 per share, or 14.73%, to close at $25.00 per share on July 29, 2026.
Then, on August 21, 2026, Bloomberg reported that Hims was put on notice by Visa Inc. for excessive customer complaints in its weight-loss subscription business, according to internal documents, adding to mounting scrutiny of its billing and cancellation policies. Reportedly, the Company was enrolled in Visa's Acquirer Monitoring Program after a surge of customer credit card disputes in July, according to the documents seen by Bloomberg. Each dispute will carry an $8 surcharge, resulting in a nearly $75,000 bill that will hit in September, the documents reportedly said.
On this news, Hims' stock price fell $2.70 per share, or 7.99%, to close at $31.08 per share on August 24, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
The investigation concerns whether Hims and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 29, 2026, the Federal Trade Commission ("FTC") filed a lawsuit against Hims, accusing it of sharing customers' medical information with third-party advertisers. The FTC's criminal complaint accuses Hims of "deceptive and unlawful privacy practices," including sharing sensitive details about patient health with Meta Platforms, Snap and Facebook's parent company.
On this news, Hims' stock price fell $4.32 per share, or 14.73%, to close at $25.00 per share on July 29, 2026.
Then, on August 21, 2026, Bloomberg reported that Hims was put on notice by Visa Inc. for excessive customer complaints in its weight-loss subscription business, according to internal documents, adding to mounting scrutiny of its billing and cancellation policies. Reportedly, the Company was enrolled in Visa's Acquirer Monitoring Program after a surge of customer credit card disputes in July, according to the documents seen by Bloomberg. Each dispute will carry an $8 surcharge, resulting in a nearly $75,000 bill that will hit in September, the documents reportedly said.
On this news, Hims' stock price fell $2.70 per share, or 7.99%, to close at $31.08 per share on August 24, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。